Valneva Scotland, the country’s largest vaccine producer, has partnered with local West Lothian-headquartered charity, Team ...

Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes PIDs to include ALPS-FAS, CTLA4 haploinsufficiency, NFKB1 ...

LONDON, October 10th 2024, - CNX Therapeutics Limited (“CNX Therapeutics”), a speciality  pharmaceutical company dedicated to improving the lives of patients through the supply of essential medicines, ...

Vapourtec creates 'mini review' showcasing key publications A recent ‘mini review’ created by Vapourtec demonstrates the scope and potential of flow biocatalysis as well as showcasing several ...

Breast Cancer Awareness Month As Breast Cancer Awareness Month begins, Paxman is raising awareness of a critical and often ...

Copenhagen, Denmark - FluoGuide A/S (“FluoGuide” or the “Company”), a biothech company specializing in precision cancer surgery, today announced the submission of the Clinical Trial Application (CTA) ...

Oxford, England, 10 October 2024 - MitoRx Therapeutics (MitoRx), a platform biotechnology company developing novel mitochondrial-targeted sulfide-donor therapeutics (mtH2SD) in obesity-related ...

Antag Therapeutics, a leading biopharmaceutical company focused on targeting the Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor to pioneer novel treatments for obesity, today announced ...

Deep expertise in leading drug discovery programs across oncology, neuroscience and epigeneticsWill drive advancement of Curve’s rich pipeline of first-in-class therapeutic assets Builds on recent ...

Paris, October 9, 2024. Sanofi advances its ambition to protect all infants from respiratory syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to be presented at the Infectious ...

Expanded production facilities and new warehouses will boost efficiency, reduce lead times and enhance regional supply chains ...

Purespring raises £80 million in a Series B financing, with Syncona committing £19.9 million[1] as part of a leading syndicate of life science investorsProceeds will be used to advance Purespring’s ...